Xeris Biopharma (NASDAQ:XERS - Get Free Report) posted its earnings results on Thursday. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.05, Zacks reports. The business had revenue of $60.10 million for the quarter, compared to analyst estimates of $58.54 million. Xeris Biopharma updated its FY 2025 guidance to EPS.
Xeris Biopharma Stock Performance
Shares of XERS stock traded up $0.35 during mid-day trading on Monday, reaching $4.59. 6,072,883 shares of the company were exchanged, compared to its average volume of 2,032,357. The company has a market capitalization of $684.28 million, a P/E ratio of -10.20 and a beta of 2.32. The business's 50 day simple moving average is $3.59 and its 200 day simple moving average is $3.27. Xeris Biopharma has a fifty-two week low of $1.69 and a fifty-two week high of $4.61.
Analyst Ratings Changes
XERS has been the subject of several analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $8.00 target price (up previously from $6.60) on shares of Xeris Biopharma in a research report on Friday. Leerink Partners upped their price target on Xeris Biopharma from $5.00 to $6.00 and gave the stock an "outperform" rating in a report on Friday. Piper Sandler reaffirmed a "neutral" rating and issued a $4.00 price objective (up previously from $3.00) on shares of Xeris Biopharma in a research report on Friday. Jefferies Financial Group reissued a "buy" rating and set a $6.00 target price (up from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. Finally, Craig Hallum upped their target price on shares of Xeris Biopharma from $5.00 to $6.50 and gave the company a "buy" rating in a research note on Friday. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $5.92.
Check Out Our Latest Report on XERS
About Xeris Biopharma
(
Get Free Report)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Featured Stories
Before you consider Xeris Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xeris Biopharma wasn't on the list.
While Xeris Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
